TREATMENT OF HYPERLIPOPROTEINEMIA (HLP) TYPE-II-A WITH A NEW PHENOXY-ISOBUTURIC ACID-DERIVATIVE, PROCETOFEN

  • 1 January 1979
    • journal article
    • research article
    • Vol. 17  (12) , 503-506
Abstract
Patients [11] with hyperlipoproteinemia (HLP) type II A, were treated for 3 mo. with a new compound, a phenoxy-isobutyric acid derivative, procetofen, at a dosage of 100 mg t.i.d. (3 times per day). Mean plasma cholesterol decreased after 3 mo. by 25% from a pretreatment value of 10.3 .+-. 0.7 mmol/l (P < 0.001). The reduction of plasma cholesterol was apparently due not only to a decrease in LDL (low density lipoprotein), as expressed from a marked reduction (15%) of the major LDL apolipoprotein moiety, apolipoprotein B, but also presumably to a decrease in VLDL (very low density lipoprotein) as reflected from a marked reduction (45%, P < 0.05) in plasma triglycerides. A marked favorable increase (28%, P < 0.001) in HDL (high density lipoprotein) major apolipoprotein moiety, apolipoprotein A, was observed. No disagreeable side-effects were recorded, except for a skin rash in 1 patient.

This publication has 0 references indexed in Scilit: